<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04491123</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0065</org_study_id>
    <nct_id>NCT04491123</nct_id>
  </id_info>
  <brief_title>Intrathecal Analgesia Effects on Cancer Patients Discomfort Symptoms</brief_title>
  <acronym>IT-ESAS</acronym>
  <official_title>Evaluation of Discomfort Symptoms in Patients With Refractory Cancer Pain and Intrathecal Analgesia Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut du Cancer de Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de NÄ«mes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncopole Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intrathecal analgesia is used in refractory cancer pain because of drug sides effects or&#xD;
      intractable pain. The aim of this approach is to improve pain management, and also to improve&#xD;
      patient comfort. This study will assess patient discomfort symptoms before and after setting&#xD;
      up intrathecal analgesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Descriptive multicenter study including patients with refractory cancer pain (unmanageable&#xD;
      drug sides effects or intractable pain) who will receive intrathecal analgesia Patient&#xD;
      discomfort symptoms will be evaluated before and after the beginning of intrathecal analgesia&#xD;
      at 15, 30, 60 and 90 days.&#xD;
&#xD;
      Moreover, the impact on patient close relatives and on return home will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number Evaluation of Edmonton symptoms</measure>
    <time_frame>up to 90 days after patient inclusion</time_frame>
    <description>Edmonton symptom assessment system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Autonomy assessment score for activities of daily living</measure>
    <time_frame>1 day</time_frame>
    <description>Autonomy assessment score for activities of daily living</description>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Refractory Cancer Pain</condition>
  <condition>Intrathecal Analgesia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        cancer patients with refractory localized cancer pain because of drug side effects or&#xD;
        intractable pain who will receive intrathecal analgesia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  patients aged 18 and older&#xD;
&#xD;
          -  obligation of affiliation or beneficiary of a social security scheme&#xD;
&#xD;
          -  patients with cancer and refractory localized cancer pain because of drug side effects&#xD;
             or intractable pain&#xD;
&#xD;
          -  localized pain in topography accessible to intrathecal analgesia (legs, abdomen and&#xD;
             pelvis, pancoast-tobias symdrom)&#xD;
&#xD;
          -  patient's informed consent for the study&#xD;
&#xD;
          -  patient able to complete the evaluation questionnaires&#xD;
&#xD;
          -  estimed vital prognosis more than three month&#xD;
&#xD;
          -  patient with all conditions for intrathecal anagelsia&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  patient with intracranial hypertension&#xD;
&#xD;
          -  refusal of patient to be included in the study&#xD;
&#xD;
          -  refusal of patient to receive intrathecal analgesia&#xD;
&#xD;
          -  patient with many refractory pain localizations not accessible to intrathecal&#xD;
             analgesia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphael RENAMBATZ-ICHAMBE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory cancer pain</keyword>
  <keyword>intrathecal analgesia</keyword>
  <keyword>pain management</keyword>
  <keyword>discomfort symptoms management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

